Melanoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-1 54
• BRAF 18
• PD-L1 21
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• RAS 2
• CTNNB1 0
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• MET 1
• HDAC 1
• IDH 1
• IL-17 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 34+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

  NCT04527549· ECOG-ACRIN Cancer Research Group· Updated 6 Oct 2026

  “Slow accrual”Registry text, quoted unchanged. Source

• Terminated

  Study of IK-595 in RAS- or RAF-altered Advanced Tumors

  NCT06270082· Ikena Oncology· Updated 19 Sept 2025

  “Limited resources and strategic priorities”Registry text, quoted unchanged. Source

• Terminated

  E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

  NCT05388877· Mayo Clinic· Updated 19 Aug 2025

  “Financial issues”Registry text, quoted unchanged. Source

• Terminated

  Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

  NCT04720417· Thomas Jefferson University· Updated 15 Jul 2025

  “Trial enrollment was stopped early by study sponsors (before the anticipated accrual of 18 patients) due to no patients having significant reduction in disease.”Registry text, quoted unchanged. Source

• Suspended

  MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

  NCT03932253· Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.· Updated 27 Mar 2024

  “Sponsor R\&D strategy adjustment”Registry text, quoted unchanged. Source

• Withdrawn

  Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

  NCT05677373· Alliance for Clinical Trials in Oncology· Updated 18 Aug 2023

  “The drug company supporting this trial has withdrawn support, including the ability to provide study agent.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults

  NCT07891286· National Cancer Institute (NCI)· Source

• Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

  NCT04557956· National Cancer Institute (NCI)· Source

• Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

  NCT04527549· ECOG-ACRIN Cancer Research Group· Source

• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Pfizer· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 22
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 47
• Metabolomics 20
• Mass Spectrometry 10
• Flow Cytometry 65
• Immunohistochemistry 106
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 121
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 57
• Machine Learning 49
• Deep Learning 44
• Cohort Studies 78
• Genome-Wide Association Study 22

• Benchmarking cell segmentation in two Spatialomics platforms with open-source software.

  Sci Rep, Oct 2026

• Spatial Proteomics as a Potential Decision-Support Layer for Early Melanoma: A Narrative Review.

  Int J Dermatol, Oct 2026

• Mapping of the hSOX10 Proximal Protein Interactome in Human Melanoma.

  J Proteome Res, May 2026

• Bioassay-guided separation and identification of the anticancer composition from Curcuma longa L. by the combination strategy of methanol gradient countercurrent chromatography and ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry.

  J Sep Sci, Nov 2022

• Hydroxylation of CYP11A1-derived products of vitamin D3 metabolism by human and mouse CYP27B1.

  Drug Metab Dispos, Mar 2013

• Combined proteomic and molecular approaches for cloning and characterization of copper-zinc superoxide dismutase (Cu, Zn-SOD2) from garlic (Allium sativum).

  Mol Biotechnol, Sept 2012

• Antiproliferative activity of methylated analogues of E- and Z-resveratrol.

  Z Naturforsch C J Biosci, Jan 2007

• Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.

  J Inorg Biochem, Jan 2006

• Identification of o-quinone/quinone methide metabolites of quercetin in a cellular in vitro system.

  FEBS Lett, Jun 2002

• Investigation on the iodination reaction of methylene blue by liquid chromatography-mass spectrometry with ionspray ionisation.

  J Chromatogr A, Aug 1999

See which targets of this disease your abstract mentions, and go to the people working on them.